Lisa Jarvis: The White House’s Drug Plan Sounds Promising — but How Will We Know?

Lisa Jarvis: The White House’s drug plan sounds promising — but how will we know?

And after months of blustery talk from President Donald Trump about lowering drug prices and cracking down on Big Pharma, his plans are finally starting to take shape, beginning with pacts with manufacturers. But before we get too excited, consumers should demand more transparency about what they’re getting from his dealmaking — and ask who is truly benefiting from the sum of his health care actions. Trump wisely put the issue of drug costs fron…

Pfizer And Trump’s Empty Promises

A new agreement between the Trump administration and drug manufacturer Pfizer will exempt the giant from proposed pharmaceutical tariffs in exchange for allegedly cutting prices for American consumers. The deal has inspired Trump to declare victory over Pfizer, telling CEO Albert Bourla, “I’m surprised you’re agreeing to this.”  Create a FREE account, or log in. Registered readers of The Lever get access to a limited number of free articles eve…

Pharma companies scramble to make deals with Trump after Pfizer scored White House praise

Pharma companies are hoping to announce deals of their own with President Trump as soon as this week, sources told STAT.

Trump announces “TrumpRx” website and Pfizer deal to slash drug prices, boost U.S. manufacturing

President Donald Trump announced a landmark agreement with Pfizer to implement “most-favored-nation” pricing for Medicaid, ensuring the U.S. pays no more than the lowest prices offered to other developed nations. The new TrumpRx direct-to-consumer platform, launching in 2026, will allow Americans to purchase prescription drugs at steep discounts (averaging 50 percent off retail prices), bypassing traditional pharmacy markups. Pfizer committed to…

Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers

The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Read more here.

The Pfizer-Trump deal: A new chapter in drug pricing or political theatre?

The approach may generate headlines while leaving the structural problems of American pharmaceutical pricing unaddressed